PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Molecular imaging for Alzheimer's disease may be available in hospitals within 1 year

3 research studies are making way for clinical use of molecular imaging as a tool for early detection of a debilitating neurodegenerative disease

2011-06-07
(Press-News.org) San Antonio, Texas (June 6, 2011)—Researchers the world over are advancing positron emission tomography (PET) as an effective method of early detection for Alzheimer's disease, a currently incurable and deadly neurological disorder. Three studies presented at SNM's 58th Annual Meeting are providing new insights into the development of Alzheimer's disease while opening the door to future clinical screening and treatments.

According to the World Health Organization, an estimated 18 million people worldwide are currently living with Alzheimer's disease—a number projected to almost double by 2025.

"The aging population around the world is escalating exponentially. From a macro perspective, amyloid imaging with PET scans can help to ascertain the likelihood that individuals will deteriorate cognitively within a few years, thereby enabling more efficient channeling of health care resources," says Kevin Ong, MD, lead author of a presented study and a research scientist at Austin Hospital, Melbourne, Australia. "From a micro perspective, planning and lifestyle modifications are possible for individuals who seek screening for Alzheimer's disease."

Molecular imaging of Alzheimer's disease is focused on detecting and analyzing the formation of a naturally occurring protein in the brain called beta-amyloid, which researchers now say is directly involved in the pathology of Alzheimer's.

"It turns out that increased amyloid is bad for cognition even in the healthy elderly," says Michael Devous, Sr., PhD, director of neuroimaging for the Alzheimer's Disease Center at UT Southwestern Medical Center, Dallas, Texas. "If you look at working memory, processing speed or fluent reasoning, three critical general domains of cognition, the more amyloid you have the worse your performance, and that's after correcting for age."

Not only is this important for imaging the disease, but it may also prove to be the key to amyloid-associated therapies and vaccines. Investigators warn that the beginning stages of the disease can precede symptoms of dementia as much as a decade or more. Imaging patients when they first show signs of mild cognitive impairment could be essential to determining their risk of future disease.

"For individuals who have already developed a measurable memory decline, a positive scan for amyloid is the most accurate predictor of progression to Alzheimer's disease," said Christopher Rowe, MD, a lead investigator for the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging and professor of nuclear medicine at Austin Hospital, Victoria, Australia. "Amyloid imaging with PET scans is expected to be widely available soon for clinical practice. It will be an important new tool in the assessment of cognitive decline."

Beta-amyloid accumulates as neurotoxic plaque in individuals preceding the onset of Alzheimer's disease, and as a result, extensive neural tissues that control major mental and physical functioning—including memory, language and motor function—are decimated. In time the disease becomes debilitating and has a devastating impact on individuals' quality of life.

Three ongoing studies presented at this year's meeting involve several years of research based on hundreds of participants ranging widely in age, cognitive ability and stage of disease. Results of these studies show that amyloid plaques build up very slowly, by an estimated two to three percent per year, and that they are often already present in healthy older individuals—12 percent of those in their 60s, 30 percent of those in their 70s and 55 percent in those over the age of 80. In one study, about 25 percent of subjects over the age of 60 had amyloid plaques. The presence of significant amyloid buildup is linked to quicker memory decline and brain atrophy.

One of the major questions in Alzheimer's imaging has been which imaging agent is best for amyloid plaque screening. Several studies have been conducted using 11C Pittsburgh Compound-B (11C-PIB), a PET imaging agent that binds to beta-amyloid in neural tissues, but two of the current studies are gauging the benefit of using F-18 labeled tracers (F-18 Florbetaben and F-18 Florbetapir), designed for routine clinical use. Both F-18 Florbetaben and F-18 Florbetapir are proving to be good predictors of progression to Alzheimer's disease, and F-18 amyloid imaging agents are the likeliest agents to move forward into clinical practice in the near future.

Researchers estimate that amyloid imaging agents will be available for clinical use in fewer than 12 months. These and further studies will continue to amass data about the development of Alzheimer's disease, and potential treatments could eventually stop and perhaps even prevent or reverse damage in the brain caused by Alzheimer's disease.

INFORMATION:

Scientific Paper 119: K. Rodrigue, K. Kennedy, M. Devous, D. Park, UT Southwestern Medical Center, Dallas, TX; "Beta-amyloid in healthy aging: Regional distribution and cognitive consequences," SNM's 58th Annual Meeting, June 4-8, 2011, San Antonio, TX.

Scientific Paper 121: C. Rowe, K. Ellis, B. Brown, P. Bourgeat, R. Head, R. Martins, O. Salvado, C. Masters, D. Ames, V. Villemagne, Austin Hospital, Melbourne, Australia; University of Melbourne, Melbourne, Australia; Edith Cowan University, Perth, Australia; Australian e-Health Research Centre, CSIRO, Brisbane, Australia; National Ageing Research Institute, Melbourne, Australia; Mental Health Research Institute, Melbourne, Australia; "The consequences of Aβ deposition in ageing and Alzheimer's disease: Results from 366 elderly subjects," SNM's 58th Annual Meeting, June 4-8, 2011, San Antonio, TX.

Scientific Paper 170: K. Ong, V. Villemagne, A. Bahar-Fuchs, F. Lamb, G. Chételat, C. Reininger, B. Putz, B. Rohde, C. Masters, C. Rowe. Austin Hospital, Melbourne, Australia; Bayer Schering Pharma, Berlin, Germany; Mental Health Research Institute, Melbourne, Australia; "Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: Predictive value of Aβ imaging with 18F-Florbetaben," SNM's 58th Annual Meeting, June 4-8, 2011, San Antonio, TX.

END



ELSE PRESS RELEASES FROM THIS DATE:

Molecular imaging finds link between obesity and low estrogen levels

2011-06-07
San Antonio, Texas (June 6, 2011)—A new study presented at SNM's 58th Annual Meeting could throw open the door to a recently established area of obesity research. Investigators have developed a novel molecular imaging agent that targets estrogenic mechanisms in the brain to find out what effect an enzyme called aromatase has on body mass index (BMI), a measurement of body fat based on height and weight. Aromatase is crucial for the production of estrogen in tissues throughout the body, including the brain. According to the World Health Organization, worldwide obesity ...

Cancer-seeking 'smart bombs' target kidney cancer cells

2011-06-07
San Antonio, Texas (June 6, 2011)—Researchers are halting kidney cancer with a novel form of radioimmunotherapy that zeroes in on antigens associated with renal cell carcinoma. Patients with progressive kidney cancer receiving up to three doses of the therapy show dramatic slowing of cancer growth and stabilization of their disease. "This study is another step forward in developing a cancer therapy that has the potential to provide additional treatment options for patients with renal cell carcinoma," says Wim Oyen, MD, professor and chairman of the department of nuclear ...

High-impact radiopeptide therapy halts neuroendocrine cancer

2011-06-07
San Antonio, Texas (June 6, 2011)—Research introduced at SNM's 58th Annual Meeting could be a sign of hope for patients with neuroendocrine cancer not responding well to standard therapies. Most radiotherapies use medical isotopes that emit beta radiation. The therapy in this study employs alpha particles, which have potential for higher potency. In fact, one single atom could be enough to kill an entire cancer cell. "Until now, the usage of alpha radionuclides was limited to direct injection into the tumor or the use of only very small doses," says Clemens Kratochwil, ...

New pretargeted radioimmunotherapy for colorectal cancer

2011-06-07
San Antonio, Texas (June 6, 2011)—Investigators at SNM's 58th Annual Meeting are presenting results from a phase 1 clinical trial for a cancer therapy that has the potential to kill colorectal tumors with less destruction of healthy tissue. Further research could lead to the use of this radioimmunotherapy to eliminate residual cancer after surgery or as a standard treatment to keep tumors from returning or spreading to other organs. "Compared to the conventional way of guiding radiation to tumors with radiolabeled antibody, pretargeted radioimmunotherapy offers an attractive ...

Combined imaging agents advance PET imaging of cancer

2011-06-07
San Antonio, Texas (June 6, 2011)—Research presented at SNM's 58th Annual Meeting is taking targeted molecular imaging to a new level by combining two commonly used imaging agents into one molecular imaging procedure. The combination of these agents creates a comprehensive examination of the extent of cancer spread within a variety of organ systems in the body. "During a time when health care costs are under intense scrutiny, consolidated procedures such as this one that provide comprehensive imaging data are a benefit to everyone—to clinicians, healthcare administrators ...

New approaches open up in spinal muscular atrophy

2011-06-07
Spinal muscular atrophy (SMA) is the leading genetic cause of death in children under 2, with no treatment other than supportive care. In the Proceedings of the National Academy of Sciences (Early Edition, week of June 6), researchers at Children's Hospital Boston show how loss or mutation of the SMA gene causes progressive muscle degeneration and weakness, and suggest a promising approach to treating the condition, sometimes referred to as a "Lou Gehrig's disease of babies." Spinal muscular atrophy, or SMA, affects one in every 1 in 6,000-10,000 infants, but an estimated ...

PET imaging determines malignancy in potential ovarian cancer cases

2011-06-07
San Antonio, Texas (June 6, 2011)—A study presented at SNM's 58th Annual Meeting may provide a new tool for detection of malignant-stage ovarian cancer. Researchers found that positron emission tomography and computed tomography (PET/CT), which images both functional and anatomical changes in the body, was useful for preoperative cancer imaging of ovarian masses when used with a radiotracer that is actively metabolized by cells as fuel. Physicians imaging patients suspected of having malignant tumors can see where cancerous cells are hyper-metabolizing the tracer and accurately ...

Gamma imaging provides superior tumor detection for dense breasts

2011-06-07
San Antonio, Texas (June 6, 2011)—A study revealed at SNM's 58th Annual Meeting is comparing the breast-tumor detection capabilities of two very different imaging technologies—breast-specific gamma imaging (BSGI), which provides functional images of breast physiology, and ultrasound—for women with complex breast imaging cases that require further evaluation. Many women who have dense breast tissue (radiodense breasts) are difficult to image using mammography, currently the gold standard of breast imaging. For women whose mammograms are not clear enough to determine whether ...

Oatmeal-labeling ideal for molecular imaging of stomach emptying

2011-06-07
San Antonio, Texas (June 6, 2011)—Patients undergoing molecular imaging to evaluate their stomach's ability to clear food are going to have an altogether new kind of breakfast. A study presented at SNM's 58th Annual Meeting has confirmed that nuclear medicine technologists can effectively use oatmeal products radiolabeled with a medical isotope to target and image the emptying of the stomach. "The current standard for molecular imaging of gastric emptying is radiolabeling egg meal, but there are patients who, either due to lifestyle choices or allergies, cannot eat eggs," ...

BUSM study finds higher adherence to dash-style diet reduces excess weight gain in adolescent girls

2011-06-07
(Boston) - Boston University School of Medicine (BUSM) researchers found that girls who followed the Dietary Approach to Stop Hypertension (DASH) diet pattern had a lower incidence of excess weight gain as measured by body mass index (BMI) over the 10-year period of their adolescence. These findings are reported in the Archives of Pediatrics & Adolescent Medicine. Obesity is a major public health problem, with 17 percent of American children overweight and 67 percent of adults either overweight or obese. Excess weight during childhood leads to numerous health problems ...

LAST 30 PRESS RELEASES:

CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injury

Melatonin receptor 1a alleviates sleep fragmentation-aggravated testicular injury in T2DM by suppression of TAB1/TAK1 complex through FGFR1

Single-cell RNA sequencing reveals Shen-Bai-Jie-Du decoction retards colorectal tumorigenesis by regulating the TMEM131–TNF signaling pathway-mediated differentiation of immunosuppressive dendritic ce

Acta Pharmaceutica Sinica B Volume 15, Issue 7 Publishes

New research expands laser technology

Targeted radiation offers promise in patients with metastasized small cell lung cancer to the brain

A high clinically translatable strategy to anti-aging using hyaluronic acid and silk fibroin co-crosslinked hydrogels as dermal regenerative fillers

Mount Sinai researchers uncover differences in how males and females change their mind when reflecting on past mistakes

CTE and normal aging are difficult to distinguish, new study finds

Molecular arms race: How the genome defends itself against internal enemies

Tiny chip speeds up antibody mapping for faster vaccine design

KTU experts reveal why cultural heritage is important for community unity

More misfolded proteins than previously known may contribute to Alzheimer’s and dementia

“Too much going on”: Autistic adults overwhelmed by non-verbal social cues

What’s driving America’s deep freezes in a warming world?

A key role of brain protein in learning and memory is deciphered by scientists

Heart attacks don’t follow a Hollywood script

Erin M. Schuman wins 2026 Nakasone Award for discovery on neural synapse function and change during formation of memories

Global ocean analysis could replace costly in-situ sound speed profiles in seafloor positioning, study finds

Power in numbers: Small group professional coaching reduces rates of physician burnout by nearly 30%

Carbon capture, utilization, and storage: A comprehensive review of CCUS-EOR

New high-temperature stable dispersed particle gel for enhanced profile control in CCUS applications

State gun laws and firearm-related homicides and suicides

Use of tobacco and cannabis following state-level cannabis legalization

Long-term obesity and biological aging in young adults

Eindhoven University of Technology and JMIR Publications announce unlimited open access publishing agreement

Orphan nuclear receptors in metabolic dysfunction-associated steatotic liver disease development

A technological breakthrough for ultra-fast and greener AI

Pusan National University researchers identify key barriers hindering data-driven smart manufacturing adoption

Inking heterometallic nanosheets: A scalable breakthrough for coating, electronics, and electrocatalyst applications

[Press-News.org] Molecular imaging for Alzheimer's disease may be available in hospitals within 1 year
3 research studies are making way for clinical use of molecular imaging as a tool for early detection of a debilitating neurodegenerative disease